Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, December 2005, p. 5185-5188, Vol. 49, No. 12
0066-4804/05/$08.00+0 doi:10.1128/AAC.49.12.5185-5188.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Department of Molecular Genetics, Microbiology and Immunology, UMDNJ-Robert Wood Johnson Medical School, 675 Hoes Lane, Piscataway, New Jersey 08854
Received 8 June 2005/ Returned for modification 26 August 2005/ Accepted 29 September 2005
Human immunodeficiency virus type 1 (HIV-1) is not eliminated from patients even after years of antiretroviral therapy, apparently due to the presence of latently infected cells. Here we describe the development of a cell-based system of latency that can be used for high-throughput screening aimed at novel drug discovery to eradicate HIV-1 infection.
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |